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Summary We have used the nitrosomethylurea-induced rat mammary tumour model to study the effects of
parenteral administration of human recombinant tumour necrosis factor (rHu-TNF) and rat gamma
interferon (IFN-y). An inbred strain of tumour bearing female Ludwig/Wistar/Olac rats were randomised to
either treatment or control groups. Two independent studies showed that combined treatment with rHu-TNF
and rat IFN-y induced significant tumour regression over 4 weeks (P=0.004, P =0.005 respectively).
Treatment with either rHu-TNF or rat IFN-y given individually did not affect the overall rate of tumour
growth (P=0.157 and 0.40 respectively) although an initial reduction in tumour size was observed during the
first few days after injection. Measurement of circulating oestradiol levels in groups in which maximum
tumour regression was observed showed no statistically significant difference when compared to the control
group. Similarly, measurement of oestrogen receptor content showed no statistically significant difference
between rHu-TNF-y or rat-IFN-y treatment or combined treatment of rHu-TNF and IFN-y with the control
group. We conclude from these observations that combined therapy with rHu-TNF and rat IFN-y may prove
to be useful new forms of treatment for human breast cancer.
Various forms of therapy are available for patients with
advanced breast disease. These can lead to a period of
remission, but in most cases do not prevent eventual relapse
with progressive disease (Henderson, 1984; Powles, 1984).
The biological factors, tumour necrosis factor (TNF) and
interferon-y (IFN-y) have been shown to be valuable in
transplantable tumour systems but have not yet been tested
in primary non-transplantable tumour. TNF is a protein
produced in the serum of mice, rats or rabbits when these
animals are primed with Bacillus calmette-guerin or
Corynebacterium parvum and with bacterial endotoxin, lipo-
polysaccharide (Carswell et al., 1975; Haranaka et al., 1984).
Macrophages, T cells and tumour cells themselves are also
sources of TNF (Mannel et al., 1980; Satomi et al., 1981).
The supernatants of human HL-60 promyelocytic leukaemia
cell line also contain TNF (Aggarwal et al., 1985a,b); TNF
has a multitude of activities in many cells, both normal and
transformed cells, in vitro, including a cytotoxic and stimu-
lating activity on different cell lines (Sugarman et al., 1985;
Fransen et al., 1986).
Studies have been carried out using TNF and IFN-y either
in combination or individually only on transplanted
tumours. These include human tumour xenografts derived
from primary breast and bowel tumours and maintained by
passage in nude mice (Balkwill et al., 1985, 1986), a human
transplantable ovarian carcinoma (NIH:OVCAR-3) and
murine methylcholanthrene-induced fibrosarcoma in mice
(Greasey et al., 1986). Combined treatment was more
effective than individual treatments despite the use of
different routes of administration.
The primary in vivo nitrosomethylurea (NMU)-induced rat
mammary tumour model is biologically similar to human
breast carcinomas (Guillino et al., 1975). Our extensive
studies have shown good correlation between the model and
the clinical response in patients and the model is now well
established for testing various endocrine agents (Williams et
al., 1982; Wilkinson et al., 1986).
Therefore we decided to study the effect of rHu-TNF and
rat-IFN-y administered individually or together using the
primary rat mammary tumour model in vivo.
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Materials and methods
Animals
Inbred virgin female Ludwig/Wistar/Olac rats (Harlan Olac
Ltd, Oxon, UK) were kept at 19°C in isolators with a
regimen of 12h light per day. They were fed CRM diet
(Labshaw, March, UK) and received water ad libitum. NMU
(Sigma Chemical Co., Poole, UK) was dissolved in distilled
water at 12.5mgml-I and adjusted to pH 5.4 with acetic
acid. One hundred and twenty rats were given three
injections of 0.5ml NMU per rat (5mg per 100 g body
weight) subcutaneously via the flank on days 0, 14 and 28
when 50 days old. The animals were then transferred to the
Biological Research Facilities, St George's Hospital Medical
School, where they were kept at 22-23°C with minimum of
8h light per day and fed SDS diet (Labshaw, March, UK).
Tumours generally developed at 36-60 days after the last
NMU injection.
Biological factors
RHu-TNF was obtained from Boehringer Ingelheim
(Bracknell, Berkshire, UK) and rat-IFN-y from the Primate
Centre (Netherlands). Each was dissolved in sodium chloride
(0.9%w/v) before use and 0.1% albumen as carrier added.
The RHu-TNF was produced in E. coli by recombinant
DNA technology purified using standard protein purification
techniques. The purity is >99% as determined by SDS
polyacrilamide gel electrophoresis. The biological potency of
rTNF was determined in the L929 cytotoxicity assay and
found to be identical to the natural substance.
The rat IFN-y was purified by the use of immuno-
absorbent chromatography using monoclonal antisera
derived from Chinese hamster ovary (CHO) cells. The
specific activity was 4 x 106 units per mg of pure
recombinant rat IFN-y was determined by assaying its pro-
tective ability against vesicular stomatitis virus in vitro using
a rat cell line.
Concerning checks for endotoxin, the TNF final product
contained <0.1 ng of endotoxin per mg of protein, based on
the USP Limulus amoebocyte lysate assay. For the IFN-y,
the amounts of endotoxin in the vials (containing 2 x 106
units) assayed by the limulus test revealed amounts below
the detection limit.
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Treatment of tumour-bearing animals
The rats commenced the course of treatment when at least
one tumour per rat had reached 1.5cm in diameter. The
rHu-TNF and rat-IFN-y were assessed together and indi-
vidually, at doses shown in Table I. In the first study
(groups 1-6), rats were randomly allocated to receive a single
tail vein injection of rHu-TNF and rat IFN-y either indi-
vidually or combined and tumour size was monitored over a
28-day period. Control animals received vehicle only, but
were otherwise treated identically. In a second study (groups
7-9) with combined rHu-TNF/rat IFN-y treatment, two
groups of animals received combined rHu-TNF and IFN-y
treatment on day 0: one group received a second injection on
day 13.
The animals were exsanguinated either when the tumours
ulcerated or on day 28. Serum samples were analysed for
oestradiol levels (Dowsett et al., 1987). In addition, all
lesions in the mammary pad areas were removed for
oestrogen receptor (ER) determination using the ligand
binding assay described previously (McGuire et al., 1973).
Tumours were considered to be ER positive if they con-
tained > 1Ofmol ER per mg cytosol protein.
Dosage determination
An initial study was carried out to determine the maximum
dose tolerated by NMU-treated animals with minimal side
effects. Twenty-four tumour-bearing animals were
randomised equally into a treated and a control group. The
control group received a single tail vein injection of vehicle.
The treatment group received a combined dose of lOO1 g
rHu-TNF and 30,000 units rat IFN-y.
Following this initial study we performed experiments in
which these agents were administered either individually at a
dosage of 1OOg rHu-TNF, 30,000 units rat-IFN-y or
combined dosage of 50jug rHu-TNF and 30,000 units rat-
IFN-y.
Tumour volume analysis
Tumour volume was recorded over the 28-day period. The
total tumour volume was estimated from the two largest
measured diameters at right angles with vernier calipers (d1
and d2) by 6in [(dld2)1] at given time t. The percentage
change in total tumour volume between day 0 and day 28
was calculated for each rat. The animals were categorised
into three groups based on this information:
(a) those with 50% or greater reduction in total volume;
(b) those with less than 50% reduction in total volume;
(c) those with no change or an increase in total tumour
volume.
Those animals that died before the termination of the
experiment were allocated to group c. Analysis was thus
based on the number of animals in each category and
treatment was compared using the Mann-Whitney U test.
Results
Comparison of combined and independent treatments with
control group (study 1)
An initial study using a lOO1 g rHu-TNF gave rise to two
deaths. For this reason we reduced the dose of rHu-TNF to
50pg in the subsequent studies. Table I shows the results of
combined and individual treatments with rHu-TNF and rat-
IFN-y. The combination of rHu-TNF and rat-IFN-y caused
significant (P =0.004) tumour regression compared to the
control group. Conversely treatment with rHu-TNF and rat-
IFN-y alone did not cause significant tumour regression
(P=0.157 and P=0.40 respectively) when compared with
their respective control group (Table I; Figures 1, 2 and 3). It
is interesting, however, that both these agents appeared to
cause a reduction in tumour size during the first 4-6 days
after administration, before the tumour growth that was
observed over the subsequent three weeks (Figures 1 and 2).
Repeat dose study (study 2)
Animals receiving a single combined dose of rHu-TNF and
rat-IFN-y responded in a similar fashion to the animals in
study 1, showing highly significant tumour regression at 28
Table I Analysis of combined and single treatment dose data
Regression
Group No. of No. of New Regression P
no. Treatment Dosage rats tumours >50% <50% Progression tumours rates (%) value
I Controls Saline 18 20 1 0 17 1 6 0.004
2 rHu-TNF+ 50Mg rHu-TNF 18 19 8 2 8 0 44
rat-IFN-y rat-IFN-y
30,000 units
Day 0
3 Controls Saline 12 15 0 1 11 0 0 0.157
4 rHu-TNF l00pg rH-TNF 12 14 0 4 8 0 0
5 Control Saline 12 12 0 0 12 0 0 0.403
6 rat-IFN-y 30,000 units 12 12 2 0 10 0 8
rat-IFN-y
Day 0
7 Control Saline 12 12 0 1 11 0 0
8 Single dose 50pg rHu-TNF 12 12 5 6 1 0 42 <0.005
30,000 units
rat-IFN-y
Day 0
9 Repeat dose 50pg rHu-TNF 10 11 7 2 1 0 58 <0.005
30,000 units
rat-IFN-y
Days 0 and 13
All rats in groups 1-6 were given a single intravenous dose of either treatment or saline as outlined in the text. Tumour
growth was recorded over the 28-day experimental period by measuring the two largest diameters at right angles with vernier
calipers. Tumour volume was estimated using the following formula: 6x [(dld2),] for each animal and categorised into three
groups: (a) those with 50% or greater reductions; (b) those with 0-50% reductions; and (c) those with an increase.208 P. SHAH et al.
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Figure 1 Effect of a single intravenous dose of 100 g rHu-TNF
(U) on the growth of NMU-induced rat mammary tumours.
Controls (Ol) were given vehicle only. Each point represents the
mean % change in tumour volume from day 0 with 95%
confidence interval. % change in tumour volume for treated
animals at the end of experiment was not statistically different
from control group (P=0.157).
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Figure 2 Effect of a single intravenous dose of 30,000 units of
rat-IFN-y (0) on the growth of NMU-induced rat mammary
tumours. Controls (El) were given vehicle only. Each point
represents the mean % change in tumour volume from day 0
with 95% confidence interval. % change in tumour volume for
treated animals at the end of experiment was not statistically
different from control group (P=0.40).
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Figure 3 Effect of combined therapy as a single intravenous
dose of 50,jg rHu-TNF and 30,000 units of rat-IFN-y (-) on the
growth of NMU-induced rat mammary tumours. Controls (Ol)
were given vehicle only. Each point represents the mean %
change in tumour volume from day 0 with 95% confidence
interval. % change in tumour volume for treated animals at the
end of experiment was statistically different from control animals
(P =0.004).
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Figure 4 Effect of a single (*) and two doses (U), 13 days
apart, of the combined 50gg rHu-TNF and 30,000 units of rat-
IFN-y therapy on the growth of NMU-induced rat mammary
tumours, compared with controls (El). Each point represents the
mean % change in tumour volume from day 0 with 95%
confidence interval. % change in tumour volume for each group
of treated animals at the end of experiment was statistically
different from control group (P= <0.005).
days (P<0.005). Animals receiving a second injection at day
13 showed significantly greater regression than the animals
given a single injection (P=0.03) (Table I and Figure 4).
Drug toxicity
The only significant toxic effect observed was in animals
receiving lOO jig rHu-TNF and 30,000 units rat-IFN-y. Of
the 12 animals recovering from this combination, two died
within 24h of injection and the remaining 10 showed weight
loss, with bleeding from eyes, nose and rectum; recovering
from the latter symptoms took 3-4 days, while body weight
was normal within two weeks.
Effect of circulating steroid hormones and tumour steroid
receptor content
We did not observe any difference in serum oestradiol after
the combined treatment or control animals (mean 143, range
27-283 (control); mean 143, range 35-267 (single combined
treatment); mean 184, range 33-380 (double combined
treatment)). The two sample t test analysis showed no
statistically significant difference between mean values of the
groups.
We have measured ER in 41 tumours. Seven out of 10
control animals had ER positive tumours (mean 93, range
<10-441fmolmg-1) compared to 9/11 animals receiving
rHu-TNF (mean 85.4, range <10-222fmolmg-1) and 5/8
animals receiving rat-IFN-y (mean 42.2, range <10-
75fmolmg-1). Ten out of 12 animals who received com-
bined therapy had ER positive tumours (mean 62.8, range
<10-136fmolmg-1). There was no significant difference
between the control and treated groups.
Discussion
This study demonstrates, for the first time, the synergistic
effect of rHu-TNF and IFN-y in carcinogen-induced primary
rat mammary tumours. We felt it important to evaluate
these agents in this primary tumour model since (a) we have
demonstrated the close similarity of this model with human
hormone-sensitive breast cancer, (b) we feel that trans-
plantable models are not suitable for evaluating agents that
may work by affecting components of the immune system
and (c) we are particularly interested in studying the effects
of these compounds in association with endocrine agents and
this model is the principal system for evaluating new
endocrine agents for the treatment of human breast cancer.
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Our study confirms the findings of Balkwill et al. (1986) in
that the combination of the two drugs was potent in causing
tumour regression whilst individually they are ineffective.
The mechanism of the synergism of TNF with IFN-y
remains obscure. Other agents such as actinomycin D also
enhance TNF cytotoxicity in vitro and it may be that both
this and IFN-y inhibit some repair mechanism. A more likely
possibility is that IFN-y induces the synthesis of TNF
receptor thus enhancing TNF cytotoxicity (Aggarwal et al.,
1985a,b) but some reports do not concur with either
this possibility or that IFN-y increases the affinity of TNF
for the receptor (Salwiz & Lippman, 1986).
Concerning the effect of these peptides on steroid receptor
binding and synthesis, some reports suggest that IFN-y
potentiates the effect of endocrine agents in vitro (Iacobelli et
al., 1986; Natoli et al., 1986), while others suggest that IFN-
y increases oestrogen receptor content (lacobelli et al., 1986;
Van Den Berg et al., 1986). Our study indicates that, in vivo,
there is little, if any, effect of the agents on ER content,
although IFN-y-treated animals had tumours with
marginally lower ER than controls.
Further studies are needed to define precisely the inter-
action of these peptides on steroid and growth factor-
induced proliferation of breast cancer cells in vivo and in
vitro. Studies by our group (Travers et al., 1988) have
demonstrated that in breast carcinomas several contain
growth factors and it is known that TNF can inhibit growth
factor effects in vitro (Sugarman et al., 1987).
We intend to initiate clinical studies designed to determine
their mechanism of action and exact scheduling with other
therapies for breast cancer.
We are grateful for the technical assistance received from the
Biological Research Facilities, St George's Hospital Medical School,
and Dr Mitch Dowsett for plasma sample analyses. We would also
like to thank Alison Lundie and Elaine Morris for typing the
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